Rehovot, Israel
March 6, 2025
Mr. Nir Nirmodi is replacing Ms. Sarit Firon, who will continue serving as a member of the board
Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, today announced the appointment of Mr. Nir Nimrodi as the new Chairperson of the Board, succeeding Ms. Sarit Firon, who has held the position since August 2021. Ms. Firon will continue to serve as a member of the Board.
As Evogene progresses toward key milestones across its subsidiaries and programs, Mr. Nimrodi’s extensive experience in scaling life sciences businesses and driving growth makes him well-suited to guide the company’s next phase. His leadership will strengthen ongoing efforts and build upon the solid foundation established under Ms. Firon’s tenure. Mr. Nimrodi, a member of the Evogene Board since September 2022, brings over two decades of extensive international experience across both start-ups and large global organizations within the life sciences, pharmaceutical, and biotechnology sectors.
“On behalf of Evogene, I am pleased to welcome Nir Nimrodi as the new Chairperson of the Board,” said Ofer Haviv, President and CEO of Evogene. “Mr. Nimrodi has been actively engaged in Evogene’s activities since 2020, initially serving as a special advisor to the Board, and subsequently as a member. With his appointment as Chairperson, I look forward to collaborating closely with him as Evogene continues on its journey. I would also like to express my gratitude to Sarit Firon for her invaluable contributions as Chairperson, and I am pleased that she will continue to support Evogene in her role as a Board member.”
“I am excited about the opportunities ahead for Evogene,” said Nir Nimrodi. “Several of the company’s assets have the potential to create significant value for Evogene and its shareholders, and I am committed to focusing on strategies that will unlock this value starting this year. Additionally, Evogene has been leveraging advanced computational capabilities to drive product innovation for the past two decades. With the growing potential of AI, a field in which Evogene is already a natural leader, we intend to further harness our expertise to advance the drug discovery process and enhance the value we bring to this space.”
In addition, Evogene’s President and CEO, Mr. Ofer Haviv, will join as member of the Board, and will remain in office until the earlier of the first annual or special general meeting of shareholders following his appointment.
Topics
Species
